Open access
Open access
Powered by Google Translator Translator

Hematology (all articles)

Guideline | Anemia management in surgical patients.

23 Sep, 2022 | 13:11h | UTC

Recommendations from the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS) – Annals of Surgery

 


Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.

23 Sep, 2022 | 13:07h | UTC

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations – The BMJ

 

Commentary on Twitter

 


A quality improvement study showed that a clinic–based aspirin deimplementation intervention can reduce inappropriate aspirin prescribing and bleeding in patients receiving warfarin for anticoagulation.

22 Sep, 2022 | 13:14h | UTC

Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation – JAMA Network Open

News Release: Stopping aspirin when on a blood thinner lowers risk of bleeding, study finds – Michigan Medicine

 

Commentary on Twitter

 


Case report and brief review | Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus.

20 Sep, 2022 | 13:17h | UTC

Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus – Canadian Medical Association Journal

 


AHA Scientific Statement | Management of patients at risk for and with left ventricular thrombus.

16 Sep, 2022 | 13:00h | UTC

Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association – Circulation

 


Review | Obesity and contraceptive use: impact on cardiovascular risk.

16 Sep, 2022 | 12:53h | UTC

Obesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure

News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology

 


NCCN Guideline | Myeloproliferative neoplasms.

15 Sep, 2022 | 13:05h | UTC

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – National Comprehensive Cancer Network

 


M-A | Blood type linked to the risk of stroke before age 60.

13 Sep, 2022 | 13:17h | UTC

Contribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)

News Releases:

Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology

Blood Type Linked To Stroke Risk Before 60 – University of Maryland

 


Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.

13 Sep, 2022 | 12:59h | UTC

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study – The Lancet Haematology

Commentaries:

CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)

CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)

 

Commentary on Twitter

 


RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.

11 Sep, 2022 | 22:24h | UTC

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial – Journal of Clinical Oncology

 


Large study unravels the risk factors for heart failure among childhood cancer survivors.

11 Sep, 2022 | 22:22h | UTC

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

 


Systematic Review | Hypoxia‐inducible factor stabilizers for the anemia of chronic kidney disease.

8 Sep, 2022 | 14:35h | UTC

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library

Summary: Are hypoxia-inducible factor stabilisers effective for management of anaemia among people with chronic kidney disease? – Cochrane Library

 


RCT | Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time.

8 Sep, 2022 | 14:34h | UTC

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link to abstract – $ for full-text)

 


48-week follow-up of a RCT | Pegcetacoplan vs. Eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

8 Sep, 2022 | 14:29h | UTC

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)

Original Study: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

 

Commentary on Twitter (thread – click for more)

 


Opinion | Tranexamic acid for safer surgery: the time is now.

7 Sep, 2022 | 12:37h | UTC

Tranexamic acid for safer surgery: the time is now – British Journal of Surgery

Related:

#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.

Update on applications and limitations of perioperative tranexamic acid.

RCT | Effect of high- vs. low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery.

Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients – this large observational study did not show an increased risk for venous thromboembolism, myocardial infarction, seizures, ischemic strokes, or transient ischemic attacks, irrespective of patient high-risk status at baseline

M-A: Intravenous tranexamic acid in surgical patients is not associated with increased risk of thromboembolic events and mortality

 


Review | Diagnosis and treatment of myelodysplastic syndromes.

7 Sep, 2022 | 12:33h | UTC

Diagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (free for a limited period)

Audio Clinical Review: Diagnosis and Management of Myelodysplastic Syndromes – JAMA

 


Cohort Study | Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria.

7 Sep, 2022 | 12:29h | UTC

Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 


Brief Review | Thromboprophylaxis in critical care.

6 Sep, 2022 | 14:41h | UTC

Thromboprophylaxis in critical care – Intensive Care Medicine

 


Review | The use of whole blood transfusion in trauma.

6 Sep, 2022 | 14:15h | UTC

The Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports

 


Systematic Review | Hydroxyurea for sickle cell disease.

5 Sep, 2022 | 14:14h | UTC

Hydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library

Summary: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library

 


Systematic Review | The effect of heparin and its preparations on disseminated intravascular coagulation mortality and hospitalization.

1 Sep, 2022 | 11:34h | UTC

The Effect of Heparin and Its Preparations on Disseminated Intravascular Coagulation Mortality and Hospitalization: A Systematic Review – International Journal of Clinical Practice

 


Long-term results of a RCT | Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in chronic lymphocytic leukemia.

31 Aug, 2022 | 11:32h | UTC

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial – Blood

Commentary: Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status – Cancer Network

 


#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.

30 Aug, 2022 | 12:12h | UTC

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT – Circulation

News Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology

Related:

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

 

Commentary on Twitter

 


#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.

29 Aug, 2022 | 12:33h | UTC

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology

Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD

 

Commentary on Twitter

 


Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.

26 Aug, 2022 | 13:05h | UTC

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.